RBC (RBC) Q4 2026 Earnings Call Transcript

RBC Bearings reported strong fiscal Q4 results, with revenue up 18.3% to $518 million, adjusted EPS up 27.9% to $3.62, and adjusted EBITDA up 21% to $168.9 million. Aerospace/Defense was the main driver, rising 41.2% year over year with backlog at about $2.3 billion, while free cash flow was $67.5 million and debt fell by $116 million in the quarter. Management guided fiscal 2027 revenue to $500 million-$510 million, with adjusted gross margin of 45.25%-45.5% and SG&A at 16.5%-16.75% of sales.

Analysis

RBC is transitioning from a cyclical aerospace supplier into a capacity-constrained, program-execution story with multiple self-reinforcing growth vectors. The key second-order implication is that backlog plus tool-time scarcity in defense platforms should keep pricing power and mix tailwinds intact for longer than the market typically discounts, especially as missile content and submarine hardware both move from “share gain” to “throughput expansion” phases over the next 12-36 months. That matters because the earnings bridge is no longer dependent on one-off M&A contribution; even if acquisition-related margins normalize, the organic base still has enough volume momentum to support double-digit EPS growth.

The most interesting underappreciated point is sequencing: marine/submarine capacity is the near-term bottleneck, while commercial OEM repricing and defense mix are the medium-term margin unlocks. This creates a setup where revenue can keep compounding before the full margin benefit shows up, which usually disappoints momentum investors in the short run but sets up a stronger rerating later as contract resets flow through in 2026-27. In other words, the market may be too focused on current-quarter gross margin and not enough on the fact that the company is deliberately spending into capacity to harvest a larger installed base of high-visibility defense work.

Industrial is the quieter bull case. Broadening demand in semis, automation, and data-center-adjacent end markets suggests RBC is getting an AI infrastructure side benefit without needing explicit AI exposure; this should improve the quality of the industrial backlog and reduce earnings cyclicality. The main counterforce is that aerospace/defense outgrowth dilutes consolidated margins in the interim, so the stock can lag if investors anchor on a near-term margin ceiling rather than the 2027 run-rate earnings power.

Risk is mostly execution, not demand: hiring, plant throughput, and supply chain availability for titanium/high-alloy inputs could delay the margin realization. If defense ramps faster than Mexico/U.S. capacity expansion, near-term working capital and SG&A can rise faster than revenue, creating a temporary “great demand, mediocre prints” problem. The setup remains favorable unless commercial aftermarket weakens materially or contract repricing gets pushed out beyond early 2027.

Key Decisions for Investors

• Go long RBC on a 6-12 month horizon; thesis is that the stock should re-rate as backlog conversion and contract repricing support a higher 2027 EPS base. Use pullbacks on any post-earnings margin skepticism to add, with downside limited by visible defense demand and debt paydown.
• Buy RBC Jan-2027 call spreads rather than outright stock if you want convexity on the 2026-27 repricing cycle; the cleanest catalyst is gradual margin expansion, not an immediate beat. Structure around the expected completion of remaining commercial OEM LTAs.
• Pair trade: long RBC / short BA over the next 3-9 months. RBC is benefiting from content gain and capacity expansion, while BA remains exposed to execution and supply-chain slippage; the spread should work if aerospace demand stays firm but supplier quality trumps OEM volume.
• For a relative-value industrial basket, long RBC vs short a lower-quality cyclicals basket or an aerospace aftermarket name with less defense exposure. RBC has a superior mix of defense, space, and industrial automation tailwinds that should support higher terminal growth.
• Take profits on any sharp move if the market starts capitalizing peak margins from the VACCO quarter as normalized earnings. The better trade is the secular compounding story into 2027, not chasing a one-quarter gross-margin surprise.